[1] |
Fava A, Petri M. Systemic lupus erythematosus: Diagnosis and clinical management[J]. J Autoimmun, 2019, 96: 1-13.
|
[2] |
Mak A, Isenberg D A, Lau CS. Global trends, potential mechanisms and early detection of organ damage in SLE[J]. Nat Rev Rheumatol, 2013, 9: 301-310.
|
[3] |
Gladman D, Ginzler E, Goldsmith C, et al. The development and initial validation of the systemic lupus international collaborating clinics American College of Rheumatology damage index for systemic lupus erythematosus[J]. Arthritis Rheum, 1996, 39: 363-369.
|
[4] |
Taraborelli M, Cavazzana I, Martinazzi N, et al. Organ damage accrual and distribution in systemic lupus erythematosus patients followed-up for more than 10 years[J]. Lupus, 2017, 26: 1197-1204.
|
[5] |
Jonsen A, Bengtsson AA, Hjalte F, et al. Total cost and cost predictors in systemic lupus erythematosus-8-years follow-up of a Swedish inception cohort[J]. Lupus, 2015, 24: 1248-1256.
|
[6] |
Thomas G, Mancini J, Jourde-Chiche N, et al. Mortality associated with systemic lupus erythematosus in France assessed by multiple-cause-of-death analysis[J]. Arthritis Rheumatol, 2014, 66: 2503-2511.
|
[7] |
Yee CS, Su L, Toescu V, et al. Birmingham SLE cohort: outcomes of a large inception cohort followed for up to 21 years[J]. Rheumatology, 2015, 54: 836-843.
|
[8] |
Urowitz MB, Gladman DD, Ibañez D, et al. Evolution of disease burden over five years in a multicenter inception systemic lupus erythematosus cohort[J]. Arthritis Care Res(Hoboken), 2012, 64: 132-137.
|
[9] |
Segura BT, Bernstein BS, Mcdonnell T, et al. Damage accrual and mortality over long-term follow-up in 300 patients with systemic lupus erythematosus in a multi-ethnic British cohort[J]. Rheumatology(Oxford), 2020, 59: 524-533.
|
[10] |
Sánchez E, Gómez LM, Lopez-Nevot MA, et al. Evid-ence of association of macrophage migration inhibitory factor gene polymorphisms with systemic lupus erythematosus[J]. Genes Immun, 2006, 7: 433-436.
|
[11] |
Foote A, Briganti EM, Kipen Y, et al. Macrophage migration inhibitory factor in systemic lupus erythematosus[J]. J Rheumatol, 2004, 31: 268-273.
|
[12] |
Akhavan PS, Su J, Lou W, et al. The early protective effect of hydroxychloroquine on the risk of cumulative damage in patients with systemic lupus erythematosus[J]. J Rheumatol, 2013, 40: 831-841.
|
[13] |
Fei Y, Zhao L, Wu L, et al. Evaluation and prediction of relapse risk in stable systemic lupus erythematosus patients after glucocorticoid withdrawal(PRESS): an open-label, multicentre, non-inferiority, randomised controlled study in China[J]. Ann Rheum Dis, 2025, 84: 274-283.
|
[14] |
Kandane-Rathnayake R, Kent JR, Louthrenoo W, et al. Longitudinal associations of active renal disease with irreversible organ damage accrual in systemic lupus erythematosus[J]. Lupus, 2019, 28: 1669-1677.
|
[15] |
Sutton EJ, Davidson JE, Bruce IN. The systemic lupus international collaborating clinics(SLICC) damage index: a systematic literature review[J]. Semin Arthritis Rheum, 2013, 43: 352-361.
|